Bulletin
Investor Alert

Market Pulse Archives

July 7, 2021, 7:48 a.m. EDT

WHO recommends Roche, Sanofi/Regeneron drugs as COVID-19 treatments, calls for lower prices

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Roche Holding AG (ROG)
  • X
    Sanofi ADR (SNY)
  • X
    Regeneron Pharmaceuticals Inc. (REGN)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

The World Health Organization began recommending the use of medicines called interleukin-6 receptor blockers as COVID-19 treatments for the severely ill, based on the findings of a large clinical study published Tuesday in JAMA. Roche Holding AG's /zigman2/quotes/206324342/delayed CH:ROG -0.63% Actemra and Sanofi /zigman2/quotes/201967021/composite SNY +0.69% and Regeneron Pharmaceuticals Inc.'s /zigman2/quotes/203149337/composite REGN +0.95% Kevzara are both approved in the U.S. as treatments for rheumatoid arthritis. The WHO said in a statement that "these are the first drugs found to be effective against COVID-19 since corticosteroids." Actemra received emergency authorization as a COVID-19 treatment last month. Research indicates the drugs can reduce the risk of death by 13% and reduce the risk of needing ventilation by 28%. However, even after recommending the drugs, the health organization called on the manufacturers to reduce prices and provide the medicines to people in low- and middle-income countries.

/zigman2/quotes/206324342/delayed
CH : Switzerland: SWX
CHF 339.35
-2.15 -0.63%
Volume: 1.13M
Sept. 21, 2021 5:30p
P/E Ratio
20.88
Dividend Yield
2.68%
Market Cap
CHF298.66 billion
Rev. per Employee
CHF574,809
loading...
/zigman2/quotes/201967021/composite
US : U.S.: Nasdaq
$ 48.22
+0.33 +0.69%
Volume: 1.15M
Sept. 21, 2021 4:00p
P/E Ratio
17.56
Dividend Yield
2.84%
Market Cap
$120.70 billion
Rev. per Employee
$413,288
loading...
/zigman2/quotes/203149337/composite
US : U.S.: Nasdaq
$ 646.95
+6.06 +0.95%
Volume: 440,623
Sept. 21, 2021 4:00p
P/E Ratio
11.62
Dividend Yield
N/A
Market Cap
$68.55 billion
Rev. per Employee
$931,393
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.